Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
February 27, 2024 15:42 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
February 27, 2024 15:40 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The...
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
February 26, 2024 19:45 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating...
Transactions in connection with share buy-back program
February 26, 2024 05:21 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
February 23, 2024 17:50 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
February 23, 2024 17:35 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 23, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and...
Transactions in connection with share buy-back program
February 19, 2024 04:40 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 19, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments...
Notice to Convene the Annual General Meeting of Genmab A/S
February 15, 2024 06:00 ET
|
Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 13, 2024 COPENHAGEN, Denmark; February 15, 2024 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on...
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
February 14, 2024 14:09 ET
|
Genmab A/S
Media Release COPENHAGEN, Denmark; February 14, 2024 Genmab filed Form 20-F for the financial year 2023 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual...
Genmab Announces Initiation of Share Buy-Back Program
February 14, 2024 11:41 ET
|
Genmab A/S
Company Announcement Repurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on March 15, 2024 COPENHAGEN, Denmark; February 14, 2024 –...